Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Hospital Chains Will Increase: Ihoken
September 3, 2001
- Air Liquid Japan: Healthcare Accounts for 8% of Total Sales
September 3, 2001
- REGULATORY NEWS IN BRIEF
September 3, 2001
- Zimmer of US Listed on NYSE
September 3, 2001
- Medical Costs at Medical Institutions Down 1.9%
September 3, 2001
- Toshiba: High-speed Multislice CT Scanners
September 3, 2001
- Minister-backed Panel to Propose Policies to Promote Drug Discovery
September 3, 2001
- Antacids Are Most Expensive in Tokyo: Inter-city Comparison of OTC Drug Prices
September 3, 2001
- PMSB Considers Introduction of Drug Master File System
September 3, 2001
- Kirin-do to Strengthen Dispensing Function
September 3, 2001
- ADR Reports on 6 Drugs Including Temocapril HCl Published
September 3, 2001
- Jovi to Tie Up with CGC Japan
September 3, 2001
- 10 New Ingredients Added to NHI Price List
September 3, 2001
- Seijo to Tie Up with Fuji Yakuhin, Mine Yakuhin
September 3, 2001
- Time Clock from Development to Approval to Be Shortened to within 5 Years?
September 3, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 3, 2001
- BUSINESS NEWS IN BRIEF
September 3, 2001
- Korosho to Present Healthcare Reform Proposals in September
September 3, 2001
- Takeda, Bayer Decide to Recall Cerivastatin in Japan
September 3, 2001
- Bungyo Rate Increased to 43.5% in April: JPA
September 3, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…